Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.
Fowler N, Kahl BS, Lee P, Matous JV, Cashen AF, Jacobs SA, Letzer J, Amin B, Williams ME, Smith S, Saleh A, Rosen P, Shi H, Parasuraman S, Cheson BD. Fowler N, et al. Among authors: cashen af. J Clin Oncol. 2011 Sep 1;29(25):3389-95. doi: 10.1200/JCO.2010.32.1844. Epub 2011 Aug 1. J Clin Oncol. 2011. PMID: 21810687 Clinical Trial.
KDM6B protects T-ALL cells from NOTCH1-induced oncogenic stress.
Issa N, Bjeije H, Wilson ER, Krishnan A, Dunuwille WMB, Parsons TM, Zhang CR, Han W, Young AL, Ren Z, Ge K, Wang ES, Weng AP, Cashen A, Spencer DH, Challen GA. Issa N, et al. Leukemia. 2023 Apr;37(4):728-740. doi: 10.1038/s41375-023-01853-9. Epub 2023 Feb 17. Leukemia. 2023. PMID: 36797416 Free PMC article.
Tolerability & long-term disease control by IGHV mutation status among CLL patients on ibrutinib arm of E1912.
Shanafelt TD, Wang XV, Hanson CA, Paietta E, O'Brien SM MD, Barrientos JC, Jelinek DF, Braggio E, Leis JF, Zhang C, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane M, Little RF, Erba HP, Stone RM, Litzow MR, Tallman MS, Kay NE. Shanafelt TD, et al. Among authors: cashen af. Blood Adv. 2024 Aug 20:bloodadvances.2024013474. doi: 10.1182/bloodadvances.2024013474. Online ahead of print. Blood Adv. 2024. PMID: 39163612 No abstract available.
Phase I-II Trial of Early Azacitidine after Matched Unrelated Donor Hematopoietic Cell Transplantation.
Xu Z, Choi J, Cooper M, King J, Fiala MA, Liu J, Pusic I, Romee R, Cashen A, Jacoby MA, Stockerl-Goldstein K, Abboud C, Vij R, Uy G, Westervelt P, Walter MJ, DiPersio JF, Schroeder MA. Xu Z, et al. Transplant Cell Ther. 2023 Nov;29(11):699.e1-699.e9. doi: 10.1016/j.jtct.2023.08.017. Epub 2023 Aug 17. Transplant Cell Ther. 2023. PMID: 37597685 Free article. Clinical Trial.
Cytokines drive the formation of memory-like NK cell subsets via epigenetic rewiring and transcriptional regulation.
Foltz JA, Tran J, Wong P, Fan C, Schmidt E, Fisk B, Becker-Hapak M, Russler-Germain DA, Johnson J, Marin ND, Cubitt CC, Pence P, Rueve J, Pureti S, Hwang K, Gao F, Zhou AY, Foster M, Schappe T, Marsala L, Berrien-Elliott MM, Cashen AF, Bednarski JJ, Fertig E, Griffith OL, Griffith M, Wang T, Petti AA, Fehniger TA. Foltz JA, et al. Among authors: cashen af. Sci Immunol. 2024 Jun 28;9(96):eadk4893. doi: 10.1126/sciimmunol.adk4893. Epub 2024 Jun 28. Sci Immunol. 2024. PMID: 38941480
Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality.
Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A, Costa LJ, Freytes CO, Gale RP, Hamadani M, Holmberg LA, Inwards DJ, Lazarus HM, Maziarz RT, Munker R, Perales MA, Rizzieri DA, Schouten HC, Smith SM, Waller EK, Wirk BM, Laport GG, Maloney DG, Montoto S, Hari PN. Fenske TS, et al. J Clin Oncol. 2014 Feb 1;32(4):273-81. doi: 10.1200/JCO.2013.49.2454. Epub 2013 Dec 16. J Clin Oncol. 2014. PMID: 24344210 Free PMC article.
Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.
Hamadani M, Hari PN, Zhang Y, Carreras J, Akpek G, Aljurf MD, Ayala E, Bachanova V, Chen AI, Chen YB, Costa LJ, Fenske TS, Freytes CO, Ganguly S, Hertzberg MS, Holmberg LA, Inwards DJ, Kamble RT, Kanfer EJ, Lazarus HM, Marks DI, Nishihori T, Olsson R, Reddy NM, Rizzieri DA, Savani BN, Solh M, Vose JM, Wirk B, Maloney DG, Smith SM, Montoto S, Saber W, Alpdogan O, Cashen A, Dandoy C, Finke R, Gale R, Gibson J, Hsu JW, Janakiraman N, Laughlin MJ, Lill M, Cairo MS, Munker R, Rowlings PA, Schouten HC, Shea TC, Stiff PJ, Waller EK. Hamadani M, et al. Biol Blood Marrow Transplant. 2014 Nov;20(11):1729-36. doi: 10.1016/j.bbmt.2014.06.036. Epub 2014 Jul 5. Biol Blood Marrow Transplant. 2014. PMID: 25008330 Free PMC article.
RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.
Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, Constine L, Shea TC, Cashen AF, Blum KA, Fenske TS, Barr PM, Phillips T, Leblanc M, Fisher RI, Cheson BD, Smith SM, Faham M, Wilkins J, Leonard JP, Kahl BS, Friedberg JW. Chen RW, et al. Among authors: cashen af. Br J Haematol. 2017 Mar;176(5):759-769. doi: 10.1111/bjh.14480. Epub 2016 Dec 19. Br J Haematol. 2017. PMID: 27992063 Free PMC article. Clinical Trial.
150 results